Eli Lilly and Company research snapshot
LLY AI stock analysis currently reads Eli Lilly and Company as a rare large-cap pharmaceutical compounder with exceptional GLP-1 demand, expanding obesity and diabetes capacity, strong Q1 2026 revenue growth, and a valuation that already prices in years of execution. At the July 8, 2026 data cutoff, LLY traded near $1,235.56 with an implied market capitalization of about $1.16 trillion. This page uses scenario analysis, technical levels, source-backed facts, and risk controls. It is informational research, not investment advice.
Current price
$1,235.56
Market cap
$1.16 trillion
AI score
82 / 100
Rating
High-growth pharma leader, valuation risk elevated
Trend status
Strong uptrend near recent highs
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Lilly sells patented medicines across diabetes, obesity, oncology, immunology, neuroscience, and related specialty categories, with Mounjaro and Zepbound driving the current growth step-up. | High |
| Moat | The moat combines patents, clinical evidence, brand trust with prescribers, manufacturing scale, payer access, regulatory capability, and a pipeline that can extend the incretin franchise. | Medium-high |
| Management | David A. Ricks and team should be judged by supply expansion, pricing discipline, pipeline returns, acquisition integration, and whether capital allocation supports durable owner earnings. | Medium |
| Financial trend | Q1 2026 revenue increased 56% to $19.799 billion and non-GAAP EPS increased 156% to $8.55, with updated 2026 revenue guidance of $82 billion to $85 billion. | High |
| Valuation | At $1,235.56 and $28.15 TTM EPS, LLY traded near 43.9x trailing earnings. The midpoint of 2026 non-GAAP EPS guidance implies about 34.1x forward earnings. | Medium-high |
| Technical trend | Investing.com showed a Strong Buy daily technical signal, price above the 50-day and 200-day moving averages, and RSI in a buy zone near 61. | Medium |
| Risk level | Risk is medium-high because product concentration, reimbursement pressure, competition from Novo Nordisk and emerging obesity assets, manufacturing reliability, and valuation matter at this scale. | Medium-high |
| AI confidence | High for descriptive research and audited calculations. Lower for exact price outcomes because pharma stocks can gap around trial, FDA, safety, and policy news. | High data confidence |
| Investment certainty | Medium certainty. LLY is a high-quality business, but a buy decision requires a view on long-duration obesity growth and tolerance for multiple compression. | Medium |
LLY AI stock forecast
The LLY AI stock forecast uses two anchors: current analyst price-target dispersion of roughly $1,135 to $1,500 from Google Finance and a three-year EPS scenario model audited with financial_rigor.py. The audited model used the $1,235.56 quote, 2026 non-GAAP EPS guidance midpoint of $36.25, and bull/base/bear growth and terminal multiple assumptions.
$2,350 to $2,550 over three years
More likely if Mounjaro, Zepbound, Foundayo, and next-generation obesity assets compound faster than expected, supply expansion unlocks demand, safety data remains supportive, and the market still pays a premium multiple near the mid-30s.
$1,600 to $1,750 over three years
More likely if EPS compounds in the mid-teens from the 2026 guidance base, revenue lands near or above guidance, payer pressure stays manageable, and investors value Lilly near 30x forward earnings.
$950 to $1,050 over three years
More likely if realized prices fall faster than volume grows, competitors narrow the clinical gap, manufacturing or safety issues emerge, pipeline readouts disappoint, or investors compress the multiple toward low-20s earnings.
LLY AI technical analysis
LLY AI technical analysis is bullish but extended as of the July 8, 2026 cutoff. Investing.com listed a Strong Buy daily signal, a 14-day RSI of 61.409, a 50-day moving average of $1,207.42, and a 200-day moving average of $1,140.04. Google Finance showed a 52-week range of $623.78 to $1,249.45.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $1,235.56 | Google Finance quote snapshot used for market cap and valuation math at the July 8, 2026 cutoff. |
| Near support | $1,207 to $1,210 | The 50-day moving average was near $1,207.42, so this area is the first trend support zone to monitor. |
| Major support | $1,140 | The 200-day moving average was near $1,140.04. A break below it would weaken the long-term trend signal. |
| Near resistance | $1,249 to $1,250 | The July 2026 high area and 52-week high were near $1,249.45, making this the immediate breakout level. |
| 50-day moving average | $1,207.42 | Investing.com listed the 50-day moving average as a buy signal. |
| 200-day moving average | $1,140.04 | Price remained above the 200-day moving average, supporting the longer-term trend. |
| Momentum | 14-day RSI 61.409 | RSI was in a buy zone but not at an extreme overbought reading. |
| Volume | Average volume about 3.36 million shares | Google Finance listed average volume near 3.36 million shares, supporting liquidity for a large-cap setup. |
| Volatility | Event-driven large-cap pharma volatility | Expect larger moves around earnings, obesity trial data, FDA updates, pricing policy, and supply news. |
| Invalidation | Close below $1,207, then $1,140 | A close below the 50-day average would weaken the short-term setup. A break below the 200-day average would be a more serious trend failure. |
LLY AI trading strategy
The LLY AI trading strategy is a rules-based framework for a high-quality but richly valued pharmaceutical leader. It is not personal advice and should be paired with live quotes, position sizing, event calendars, filings, and risk limits.
Watch for LLY to hold above the 50-day moving average and break the $1,249 to $1,250 resistance area with volume confirmation.
A close below the $1,207 support area or a failed breakout after earnings should invalidate the short-term setup.
If LLY pulls back toward the 50-day or 200-day average without a new product, safety, or guidance problem, compare the price reaction with Mounjaro, Zepbound, Foundayo, and pipeline evidence.
Do not average down without a defined loss limit because drug, payer, or FDA news can turn a support level into a thesis break.
Track incretin volume growth, realized prices, manufacturing capacity, 2026 revenue guidance, non-GAAP EPS guidance, R&D productivity, acquisition spending, and obesity competitor data.
Reduce confidence if revenue growth depends mainly on price, if supply expansion misses, if payer access tightens, or if EPS growth fails to convert into free cash flow.
Investment research summary
Lilly turns proprietary science, clinical evidence, regulatory approvals, manufacturing capacity, and physician adoption into recurring medicine revenue for chronic and specialty disease markets.
The moat is strongest in diabetes and obesity where clinical data, brand trust, payer access, manufacturing scale, device know-how, and patent protection reinforce each other.
The thesis fails if GLP-1 pricing falls faster than volume grows, if safety or tolerability issues hurt adoption, if competitors produce better outcomes, or if the stock multiple compresses before earnings catch up.
Management has created a category-defining growth engine, but future judgment depends on capacity execution, disciplined business development, transparent pricing, and the ability to keep the pipeline productive.
Metabolic disease treatment is a long-duration health trend, and Lilly is positioned near the center of it. The same trend attracts intense competition, payer scrutiny, and regulatory attention.
LLY is priced as an elite growth compounder, not as a normal pharma stock. Margin of safety depends on whether earnings can compound fast enough to absorb a premium multiple.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| LLY price | $1,235.56 | Google Finance quote snapshot | July 8, 2026 |
| Market capitalization | $1.16 trillion | Google Finance quote snapshot | July 8, 2026 |
| Shares outstanding | 941.74 million | Google Finance quote snapshot | July 8, 2026 |
| Q1 2026 revenue | $19.799 billion, up 56% | Eli Lilly Q1 2026 press release | July 8, 2026 |
| Q1 2026 reported net income | $7.396 billion | Eli Lilly Q1 2026 press release | July 8, 2026 |
| 2026 guidance | Revenue $82 billion to $85 billion, non-GAAP EPS $35.50 to $37.00 | Eli Lilly Q1 2026 press release | July 8, 2026 |
| FY2025 revenue | $65.179 billion | Eli Lilly FY2025 results release | July 8, 2026 |
| FY2025 net income | $20.64 billion | StockAnalysis cross-check | July 8, 2026 |
| Cash and equivalents | $7.3 billion at FY2025 year-end | Eli Lilly 2025 annual report | July 8, 2026 |
| Technical signal | Strong Buy, RSI 61.409, 50-day MA $1,207.42, 200-day MA $1,140.04 | Investing.com technical summary | July 8, 2026 |
| Analyst price target range | $1,135 low, $1,305 average, $1,500 high | Google Finance analyst summary | July 8, 2026 |
This LLY AI stock analysis is an informational research tool. It is not investment advice, a recommendation, or a promise of future returns. Forecast ranges are scenarios based on available public data as of July 8, 2026 and can be wrong if earnings, valuation multiples, clinical data, regulation, competition, or market conditions change.
